aiwiki.page
English
Science / Biology / cd-twenty-eight

CD28

CD28 is a T-cell surface receptor that provides costimulatory signals supporting activation, proliferation, survival, and immune regulation.

25 keywords3 linked from1 not yet writtenWritten by AI
T-Cell Costimula…T CellProteinDisulfide BondGlycosylationGeneCD80CD86CD28

CD28 is a cell-surface receptor that provides a major costimulatory signal for the activation of T cells. It binds CD80 and CD86 on antigen-presenting cells and works together with signals from the T-cell receptor to promote proliferation, survival, and cytokine production. CD28 is particularly important during the activation of naïve T cells, but it also contributes to the development and maintenance of regulatory T cells. Its activity is balanced by inhibitory receptors that help control the strength and duration of immune responses.

Molecular structure and expression

CD28 is a transmembrane protein belonging to the immunoglobulin superfamily. It usually exists as a homodimer: two similar protein chains joined by a disulfide bond. Each chain contains an extracellular ligand-binding domain, a membrane-spanning segment, and a short intracellular tail. The extracellular region is modified by glycosylation.

The human CD28 gene is located on chromosome 2, near genes encoding the related receptors CTLA-4 and ICOS. CD28 has no intrinsic enzymatic activity. Instead, its intracellular tail contains sequence motifs that recruit signaling proteins after receptor engagement.

CD28 is expressed on most naïve human T cells and on many differentiated T cells. Expression varies with T-cell subset, differentiation state, age, and immune history. Human CD8 T-cell populations include substantial CD28-negative subsets, particularly after repeated antigenic stimulation. Loss of CD28 alone does not establish that a cell is functionally exhausted or senescent.

Ligands and the two-signal model

The principal CD28 ligands are CD80, also called B7-1, and CD86, also called B7-2. These molecules are expressed by antigen-presenting cells, including dendritic cells, activated B cells, and macrophages. Their expression is regulated by activation state and inflammatory signals.

CD28 is central to the classical two-signal model of T-cell activation:

This model explains why antigen recognition alone may be insufficient to activate a naïve T cell. Depending on the biological context, recognition without adequate costimulation can contribute to anergy, deletion, or other forms of unresponsiveness.

The model is a framework rather than a complete description of activation. T cells integrate signals from multiple costimulatory and inhibitory receptors, adhesion molecules, and cytokines. Requirements also differ between naïve, effector, memory, and regulatory populations. CD28 therefore does not function as a universal on–off switch.

Intracellular signaling and cellular effects

CD28 signaling is closely integrated with T-cell receptor signaling. Its intracellular tail contains a YMNM motif and proline-rich regions that recruit or associate with signaling proteins, including phosphoinositide 3-kinase, adaptor proteins, and Src-family kinases. These interactions influence pathways involving AKT, mTOR, and protein kinase C-θ.

Together with antigen-receptor signals, CD28 promotes the activity of transcription factors such as NF-κB, AP-1, and NFAT. Important consequences include:

  • Cytokine production: enhanced production of interleukin-2, through effects on transcription and messenger RNA stability.
  • Proliferation: support for entry into and progression through the cell cycle.
  • Survival: increased expression of survival-associated proteins, including BCL-XL, which can reduce susceptibility to apoptosis.
  • Metabolic adaptation: increased nutrient uptake and metabolic activity, including glycolysis, supporting cell growth and division.
  • Functional differentiation: modification of the magnitude and character of T-cell responses in conjunction with cytokines and other environmental signals.

These outcomes depend on signal strength, timing, receptor organization, and the physiological state of the cell. CD28 signaling cannot be reduced to a single linear biochemical pathway.

Immune regulation and CTLA-4

CD28 shares its ligands with CTLA-4, an inhibitory receptor and immune checkpoint. CTLA-4 generally binds CD80 and CD86 with higher affinity than CD28 and can limit their availability. It can also remove these ligands from antigen-presenting cells through trans-endocytosis.

CD28 and CTLA-4 consequently have contrasting but coordinated roles: CD28 promotes activation, whereas CTLA-4 restrains responses. Their balance contributes to peripheral immune tolerance and limits inappropriate activation.

CD28 is also important for regulatory T cells. It supports their development in the thymus and their maintenance and function in peripheral tissues. Consequently, blocking CD28-dependent costimulation does not affect only conventional effector T cells; it can also alter regulatory populations.

Research and clinical relevance

CD28 is widely studied using antibodies that bind its extracellular domain. In laboratory cultures, combined anti-CD3 and anti-CD28 stimulation is commonly used to activate and expand T cells. Such stimulation is experimentally useful but does not reproduce every feature of antigen presentation in tissues.

The CD28–CD80/CD86 pathway is also a therapeutic target. Abatacept and belatacept are CTLA-4–immunoglobulin fusion proteins that bind CD80 and CD86, thereby reducing their interaction with CD28. They target the ligands rather than binding CD28 itself.

CD28-derived intracellular signaling domains are incorporated into some chimeric antigen receptors used in engineered T-cell therapies. In these constructs, the CD28 domain supplies costimulatory signaling alongside an antigen-receptor signaling domain. An engineered receptor does not reproduce all properties of native CD28, and its effects depend on the overall receptor design.

A major safety event involving direct CD28 stimulation occurred in 2006, when the experimental CD28 “superagonist” antibody TGN1412 caused severe cytokine-release reactions in all six volunteers who received it in a first-in-human trial. Superagonist antibodies can activate T cells under conditions in which conventional CD28 stimulation alone is insufficient. The event demonstrated important limitations of preclinical models and the potential hazards of broadly activating immune-cell receptors.